SINGAPORE] Automotive-solutions provider Vin’s Holdings could be the first listing on the Singapore Exchange (SGX) this year. Read more at The Business Times.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...

Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...